Hook / Thesis
I've got my eye on Tarsus (TARS) right now because the stock offers a defined entry and an asymmetric upside with clear near-term catalysts. The company is turning into a primarily commercial play driven by XDEMVY, its FDA-approved treatment for Demodex blepharitis. Sales are already material (2025 net product sales of $451.4 million) and management is guiding to a full-year 2026 XDEMVY revenue range of $670-700 million — that revenue momentum, paired with gross margins near 93%, gives the equity a real earnings leverage despite current GAAP losses.
Practically: the market has priced in earnings pain (consensus shows an expected quarterly loss and a negative Earnings ESP in recent previews), which can create a short-term overreaction. That creates a tactical opportunity to add a mid-duration long (45 trading days) to capture post-print volatility, continued commercial cadence, and potential short-covering. Current technicals and short-interest dynamics support a measured long, provided a tight stop is used to control downside.
Business in plain terms - and why the market should care
Tarsus is a commercial-stage biopharma focused on eye care. Its lead product, XDEMVY, treats Demodex blepharitis — an underdiagnosed but high-prevalence eyelid condition. Management has converted initial regulatory success into real sales traction: XDEMVY net product sales were $451.4 million in 2025 and the company reported Q1 2026 XDEMVY sales in excess of $145 million (an 85% YoY increase). Management reiterated full-year 2026 guidance for XDEMVY sales of $670-700 million. For investors, that story translates into a high-margin commercial engine (gross margins reported around 93%) that can rapidly scale revenue while fixed selling and R&D costs roll off relatively slowly.
Beyond XDEMVY, Tarsus is advancing other eye-care programs (TP-03 in late-stage development, TP-04 for ocular rosacea) and has added a late-stage antiseptic asset via an iRenix acquisition (IRX-101). Those pipeline items are optional upside for the equity; the primary fundamental driver right now is pure commercial execution of XDEMVY.
Support for the trade - numbers that matter
| Metric | Value |
|---|---|
| Current price | $74.88 |
| Market cap | $3.69B |
| 52-week range | $53.89 - $91.53 |
| Price-to-sales | 5.78 |
| EV / Sales | 5.56 |
| Gross margin (commercial) | ~93% |
| Free cash flow (most recent) | $56.0M |
| Cash on balance (reported metric) | ~$1.16B |
| Short interest (most recent) | ~5.7M shares; days to cover ~5.7 |
Those numbers frame the trade. At a $3.7 billion market cap and an EV just over $3.37 billion, the market is effectively valuing Tarsus as a growth commercial company with high margins but near-term GAAP losses. Price-to-sales of ~5.8 and EV/Sales ~5.6 look rich compared with large-cap pharmaceutical franchises, but the valuation starts to make sense when you consider (1) very high gross margins, (2) rapid revenue growth (XDEMVY sales doubling and guide of $670-700M for 2026), and (3) modest financial leverage (debt to equity ~0.21). Free cash flow of about $56 million shows early cash generation; importantly, the company also carries meaningful cash (~$1.16 billion) which gives runway to expand commercial reach and fund pipeline work without immediate capital raises.
Technicals and supply/demand notes
Technically, short-term momentum is constructive: the 9/21/50-day EMA cluster sits around the low $72 area and the stock is trading slightly above those averages. The Relative Strength Index around 55 is neutral-to-positive and MACD shows bullish momentum. Short interest runs roughly 5.7 million shares with days-to-cover near 5.7 on the most recent settlement — not an extreme squeeze ratio but enough to amplify moves during a surprise earnings print or a strong sales update. Recent short-volume data also shows large intraday short activity, consistent with traders positioning for downside into earnings.
Trade plan - exact execution
- Direction: Long
- Entry: 74.88
- Stop loss: 67.00
- Target: 85.00
- Horizon: mid term (45 trading days) - this gives time for the market to digest the upcoming earnings or sales cadence, for management commentary to land, and for any short-covering to occur into better-than-feared outcomes.
Why these levels? Entry at $74.88 is effectively the current market price and gives us a purchase near the cluster of short-term moving averages. A stop at $67 limits downside to roughly 10% and sits below the mid-$60s area where previous short-term support and the lower end of recent trading activity reside. The target at $85 captures a move back toward the 52-week high zone and represents a sensible near-term upside given continued strong top-line execution and the potential for the market to re-rate on improving operating leverage.
Catalysts to watch
- Quarterly results / management commentary - a beat on sales or stronger-than-expected guidance could produce a sharp move higher.
- Sales cadence updates / market-share disclosures for XDEMVY - continued rapid adoption would justify a multiple expansion.
- Conference presentations where management provides commercial metrics or field-level data supporting penetration.
- Pipeline or acquisition integration updates (e.g., progress integrating iRenix/IRX-101) that expand the commercial footprint.
- Short-covering dynamics after a softer-than-expected print that still includes strong sales — that combination can paradoxically create a snapback.
Risks and counterarguments
Every trade starts with why it can fail. Here are the main risks to this plan:
- Earnings miss / guidance cut: Analysts expect a quarterly loss and consensus estimates show a negative Earnings ESP. A materially worse-than-expected print or weaker guidance could ignite heavier selling and invalidate the setup, potentially pushing TARS below the $67 stop.
- Commercial durability questions: Rapid early adoption can slow. If refill rates or prescribing patterns weaken, the valuation premised on sustained XDEMVY growth would come under pressure.
- Regulatory or safety headlines: Eye-care drugs can attract adverse event reports that temporarily compress multiples even if long-term fundamentals are unchanged.
- Multiple contraction: With price-to-sales near 5.8 and P/B above 10, the stock is priced for growth. If macro sentiment or sector multiples compress, even solid top-line growth may not prevent share weakness.
- Short-selling pressure: A sustained increase in short interest or aggressive short-volume days could grind the stock lower before any short-squeeze relief can appear.
Counterargument to the bullish thesis: The market's skepticism is not crazy — Tarsus still reports GAAP losses and trades at a premium multiple. If profitability does not improve or if revenue growth decelerates versus the high bar implied by guidance, the stock can quickly give back gains. In other words, valuation is already forward-looking; strong execution must continue to justify current prices.
What would change my mind
I will abandon this trade if the company reports materially weaker XDEMVY demand metrics (a clear sequential slowdown in net product sales or worse-than-expected refill/penetration metrics) or if management materially lowers its 2026 sales guidance. Conversely, a sustained big beat that leads to guidance raise or a consistent quarter of positive operating leverage and expanding gross profit conversion would make me upgrade the stance from a tactical swing to a longer-term position.
Bottom line
Tarsus is a commercial growth story with real sales momentum and a balance sheet that supports continued execution. The market's focus on a near-term earnings miss is creating a tradable setup: buy around $74.88 with a $67 stop and an $85 target over 45 trading days. The trade is not without risk — especially on the print and multiple compression — so size the position accordingly and keep the stop in place. If management confirms durable XDEMVY adoption and the company shows operating leverage, this trade will work; if not, accept the disciplined exit and wait for a clearer evidence of re-acceleration.